Laura Bukavina/X
Jun 16, 2025, 11:13
Laura Bukavina: Real-World Use of ctDNA Assay in Non–Muscle-Invasive Bladder Cancer
Laura Bukavina, Urologic Oncologist at Cleveland Clinic, posted on X:
“Practice-changing insights
ctDNA role in high risk NMIBC ( T1HG and BCG unresponsive). First pub Cleveland Clinic Urology as we continue to learn more. ctDNA is detectable in 35% of highest-risk NMIBC. ctDNA+ often flags recurrence or upstaging ~3mo before imaging.
In BCG-naïve: +ctDNA to restage with MRI to rule out cT2+
In BCG-unresponsive: +ctDNA = poor prognostic factor to favor cystectomy and lead to salvage intravesical.”
Title: Real-World Experience with a Commercial Circulating Tumor DNA Assay in Non–muscle-invasive Bladder Cancer
Authors:
Read The Full Article at European Urology Oncology.
More posts featuring Laura Bukavina on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 16, 2025, 11:04
Jun 16, 2025, 11:01
Jun 16, 2025, 10:58
Jun 16, 2025, 10:48
Jun 16, 2025, 10:28
Jun 16, 2025, 09:39